UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer’s disease

Brain research bulletin, 2019-11, Vol.153, p.223-231

2019

Volltextzugriff (PDF)

Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts

Frontiers in pharmacology, 2023-10, Vol.14, p.1254706-1254706

2023

Volltextzugriff (PDF)

A meta-analysis of efficacy and safety of PDE5 inhibitors in the treatment of ureteral stent-related symptoms

Annals of palliative medicine, 2021-02, Vol.10 (2), p.1000-1011

2021

Volltextzugriff (PDF)

Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review

Pulmonary circulation, 2020-07, Vol.10 (3), p.1-8

2020

Volltextzugriff (PDF)

Erectile Dysfunction and Dyslipidemia: Relevance and Role of Phosphodiesterase Type-5 Inhibitors and Statins

Journal of sexual medicine, 2008-05, Vol.5 (5), p.1066-1078

2008

Volltextzugriff (PDF)

Spectroscopic determination of hydrophobic adulterant tadalafil by aptasensor based ellipsometry

Talanta (Oxford), 2024-01, Vol.266 (Pt 1), p.124940-124940, Article 124940

2024

Volltextzugriff (PDF)

New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil

Frontiers in oncology, 2021-02, Vol.11, p.627229-627229

2021

Volltextzugriff (PDF)

Fluorescence “turn-on” sensing for five PDE5 inhibitors in functional food based on bimetallic nanoclusters

Analytica chimica acta, 2023-11, Vol.1280, p.341883-341883, Article 341883

2023

Volltextzugriff (PDF)

Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States

Journal of sexual medicine, 2021-09, Vol.18 (9), p.1511-1523

2021

Volltextzugriff (PDF)

Computational analysis of natural compounds as potential phosphodiesterase type 5A inhibitors

Computational biology and chemistry, 2024-12, Vol.113, p.108239, Article 108239

2024

Volltextzugriff (PDF)

Application of terahertz Time-Domain spectroscopy and chemometrics-based whale optimization algorithm in PDE5 inhibitor detection

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2024-04, Vol.310, p.123894, Article 123894

2024

Volltextzugriff (PDF)

Efficacy of Udenafil for the Treatment of Erectile Dysfunction up to 12 Hours after Dosing: A Randomized Placebo-Controlled Trial

Journal of sexual medicine, 2010-06, Vol.7 (6), p.2209-2216

2010

Volltextzugriff (PDF)

Erectile dysfunction and diabetes: A melting pot of circumstances and treatments

Diabetes/metabolism research and reviews, 2022-02, Vol.38 (2), p.e3494-n/a

2022

Volltextzugriff (PDF)

Comprehensive management of erectile dysfunction in diabetes mellitus: pathogenesis, treatment modalities, and future perspectives

Quality in Sport, 2024-08, Vol.17

2024

Volltextzugriff (PDF)

Undeclared phosphodiesterase type 5 inhibitors (PDE5Is) in food supplements on the Croatian market analyzed by liquid chromatography time-of-flight mass spectrometry (LC-QTOF-MS)

Microchemical journal, 2024-08, Vol.203, p.110917, Article 110917

2024

Volltextzugriff (PDF)

Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5)

ACS chemical neuroscience, 2018-07, Vol.9 (7), p.1625-1636

2018

Volltextzugriff (PDF)

The Effect of PDE5 Inhibitors on the Male Reproductive Tract

Current pharmaceutical design, 2021-01, Vol.27 (23), p.2697-2713

2021

Volltextzugriff (PDF)

Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?

The Journal of urology, 2024-03, Vol.211 (3), p.400-406

2024

Volltextzugriff (PDF)

A review on pharmacological options for the treatment of erectile dysfunction: state of the art and new strategies

Expert opinion on pharmacotherapy, 2023-08, Vol.24 (12), p.1375-1386

2023

Volltextzugriff (PDF)

A review search of sildenafil uses in human and in the veterinary medicine

AIP Conference Proceedings, 2023, Vol.2475 (1)

2023

Volltextzugriff (PDF)

Survival of Japanese Patients with Pulmonary Arterial Hypertension after the Introduction of Endothelin Receptor Antagonists and/or Phosphodiesterase Type-5 Inhibitors

Internal Medicine, 2012, Vol.51(19), pp.2721-2726

2012

Volltextzugriff (PDF)

A Brief Overview of Cholinergic and Phosphodiesterase-5 Inhibitors in Diabetic Bladder Dysfunction

International journal of molecular sciences, 2024-10, Vol.25 (19), p.10704

2024

Volltextzugriff (PDF)

Acute Unloading Effects of Sildenafil Enhance Right Ventricular–Pulmonary Artery Coupling in Heart Failure

Journal of cardiac failure, 2021-02, Vol.27 (2), p.224-232

2021

Volltextzugriff (PDF)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews

Frontiers in pharmacology, 2021-09, Vol.12, p.735708-735708

2021

Volltextzugriff (PDF)

The first total syntheses of lorneic acids C and D and improved synthetic routes to lorneic acids A and J

Tetrahedron, 2024-08, Vol.163, p.134139, Article 134139

2024

Volltextzugriff (PDF)

1 – 25 von 676

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(608)
Mit Volltextzugriff
(483)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(557)
Life Sciences & Biomedicine
(539)
Humans
(343)
Male
(332)
Erectile Dysfunction
(293)
Pde5 Inhibitors
(257)
Urology & Nephrology
(210)
Animals
(190)
Pde5 Inhibitor
(188)
Erectile Dysfunction - Drug Therapy
(160)
Pharmacology & Pharmacy
(152)
Pde5
(148)
Tadalafil
(138)
Sildenafil
(133)
Sildenafil Citrate
(127)
Middle Aged
(112)
Biological And Medical Sciences
(106)
Medical Sciences
(102)
Phosphodiesterase 5 Inhibitors - Pharmacology
(96)
Phosphodiesterase 5 Inhibitors - Therapeutic Use
(96)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer’s disease

Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts

A meta-analysis of efficacy and safety of PDE5 inhibitors in the treatment of ureteral stent-related symptoms

Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review

Erectile Dysfunction and Dyslipidemia: Relevance and Role of Phosphodiesterase Type-5 Inhibitors and Statins

Spectroscopic determination of hydrophobic adulterant tadalafil by aptasensor based ellipsometry

New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil

Fluorescence “turn-on” sensing for five PDE5 inhibitors in functional food based on bimetallic nanoclusters

Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States

Computational analysis of natural compounds as potential phosphodiesterase type 5A inhibitors

Application of terahertz Time-Domain spectroscopy and chemometrics-based whale optimization algorithm in PDE5 inhibitor detection

Efficacy of Udenafil for the Treatment of Erectile Dysfunction up to 12 Hours after Dosing: A Randomized Placebo-Controlled Trial

Erectile dysfunction and diabetes: A melting pot of circumstances and treatments

Comprehensive management of erectile dysfunction in diabetes mellitus: pathogenesis, treatment modalities, and future perspectives

Undeclared phosphodiesterase type 5 inhibitors (PDE5Is) in food supplements on the Croatian market analyzed by liquid chromatography time-of-flight mass spectrometry (LC-QTOF-MS)

Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5)

The Effect of PDE5 Inhibitors on the Male Reproductive Tract

Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?

A review on pharmacological options for the treatment of erectile dysfunction: state of the art and new strategies

A review search of sildenafil uses in human and in the veterinary medicine

Survival of Japanese Patients with Pulmonary Arterial Hypertension after the Introduction of Endothelin Receptor Antagonists and/or Phosphodiesterase Type-5 Inhibitors

A Brief Overview of Cholinergic and Phosphodiesterase-5 Inhibitors in Diabetic Bladder Dysfunction

Acute Unloading Effects of Sildenafil Enhance Right Ventricular–Pulmonary Artery Coupling in Heart Failure

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews

The first total syntheses of lorneic acids C and D and improved synthetic routes to lorneic acids A and J

Suchergebnisse filtern